ALNYLAM PHARMACEUTICALS, INC. Proceeds from (Repayments of) Secured Debt
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Proceeds from (Repayments of) Secured Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfSecuredDebt · last filed 2025-02-13
- ALNYLAM PHARMACEUTICALS, INC. proceeds from (repayments of) secured debt for fiscal 2024 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from (repayments of) secured debt for fiscal 2023 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from (repayments of) secured debt for fiscal 2022 was -$762.11M, a 252.42% decline from fiscal 2021.
- ALNYLAM PHARMACEUTICALS, INC. proceeds from (repayments of) secured debt for fiscal 2021 was $500.00M.
| Period end | Proceeds from (Repayments of) Secured Debt 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-13 |
| 2022-12-31 | -$762.11M 10-K · filed 2025-02-13 |
| 2021-12-31 | $500.00M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |